Results 131 to 140 of about 106,545 (283)
CPT: Pharmacometrics &Systems Pharmacology, EarlyView.ABSTRACT Furmonertinib demonstrated potent efficacy as a newly developed tyrosine kinase inhibitor for the treatment of patients with epidermal growth factor receptor (EGFR) mutation‐positive non‐small cell lung cancer. In vitro research showed that furmonertinib is metabolized to its active metabolite AST5902 via the cytochrome P450 (CYP) enzyme ...
Yali Wu +8 more
wiley +1 more source
Small Science, EarlyView.Hyaluronic acid‐decorated imatinib‐loaded liposomes are developed to specific target CD44 receptor expressed by interstitial lung fibrosis cells, demonstrating higher uptake than empty liposomes. Based on promising in vitro data, they are administered intratracheally and intraperitoneally in a mouse bleomycin model, assessing their ability to decrease ...
Sara Bozzini +13 more
wiley +1 more source
Interferon-α, but not the ABL-kinase inhibitor imatinib (STI571), induces expression of myeloblastin and a specific T-cell response in chronic myeloid leukemia [PDF]
, 2002 Andreas Burchert +14 more
openalex +1 more source
The Journal of Dermatology, Volume 52, Issue 7, Page 1146-1151, July 2025.ABSTRACT Background Pathogenic BRAF mutations drive constitutive MAPK pathway activation in melanoma, and targeted therapies with dabrafenib plus trametinib have improved outcomes in the adjuvant setting. However, the optimal duration of adjuvant therapy remains unclear.
Dong‐Dong Jia +12 more
wiley +1 more source
Andrology, EarlyView.Abstract Background Imatinib and dasatinib are tyrosine kinase inhibitors (TKIs) increasingly used to treat several diseases in both children and adults at fertile age. We have previously shown that imatinib has adverse effects on developing testis, and imatinib‐treated male patients have been reported to have reduced sperm counts.
Anna Eggert +10 more
wiley +1 more source
Imatinib in the treatment of chronic myeloid leukemia: current perspectives on optimal dose
Blood and Lymphatic Cancer: Targets and Therapy, 2015 Joanna Waclaw,1 Tomasz Sacha,1 Tomasz Stoklosa,21Department of Hematology, Jagiellonian University Collegium Medicum, Kraków, 2Department of Immunology, Medical University of Warsaw, Warsaw, Poland Abstract: Imatinib was the first tyrosine kinase
Waclaw J, Sacha T, Stoklosa T
doaj
Clinical course of thrombocytopenia in patients treated with imatinib mesylate for accelerated phase chronic myelogenous leukemia [PDF]
, 2002 Hendrik W. van Deventer +8 more
openalex +1 more source
Andrology, EarlyView.Abstract Background Growing evidence indicates that paternal condition significantly influences pregnancy outcomes and offspring health. However, assessing the safety of paternal drug exposure via randomized controlled trials poses ethical challenges, and relevant clinical studies consume a lot of resources to evaluate only a few drugs.
Yanbin Zeng, Wanlong Lin, Wei Zhuang
wiley +1 more source
High frequency of point mutations clustered within the adenosine triphosphate–binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance [PDF]
, 2002 Susan Branford +8 more
openalex +1 more source
British Journal of Haematology, EarlyView.Proposed management of newly diagnosed Philadelphia chromosome‐positive (Ph+) acute lymphoblastic leukaemia (ALL) in transplant‐eligible patients. Suggested considerations when deciding the treatment pathway available to a newly diagnosed Ph+ ALL patient that would be deemed transplant eligible. Summary Acute lymphoblastic leukaemia (ALL) in 20%–30% of
Naranie Shanmuganathan, Andrew Grigg
wiley +1 more source